133 related articles for article (PubMed ID: 8913795)
1. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia S; Montgomery JA; Johnson HG; Walsh GM
Immunopharmacology; 1996 Oct; 35(1):53-63. PubMed ID: 8913795
[TBL] [Abstract][Full Text] [Related]
2. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
Bantia S; Miller PJ; Parker CD; Ananth SL; Horn LL; Kilpatrick JM; Morris PE; Hutchison TL; Montgomery JA; Sandhu JS
Int Immunopharmacol; 2001 Jun; 1(6):1199-210. PubMed ID: 11407314
[TBL] [Abstract][Full Text] [Related]
3. Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells.
Conry RM; Bantia S; Turner HS; Barlow DL; Allen KO; LoBuglio AF; Montgomery JA; Walsh GM
Immunopharmacology; 1998 Jul; 40(1):1-9. PubMed ID: 9776473
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vivo efficacy of BCX-1777 and cyclosporin in xenogeneic graft-vs.-host disease: the role of dGTP in antiproliferative action of BCX-1777.
Banti S; Miller PJ; Parker CD; Ananth SL; Horn LL; Babu YS; Sandhu JS
Int Immunopharmacol; 2002 Jun; 2(7):913-23. PubMed ID: 12188033
[TBL] [Abstract][Full Text] [Related]
5. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
Bantia S; Ananth SL; Parker CD; Horn LL; Upshaw R
Int Immunopharmacol; 2003 Jun; 3(6):879-87. PubMed ID: 12781704
[TBL] [Abstract][Full Text] [Related]
7. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor.
Wada Y; Yagihashi A; Terasawa K; Miyao N; Hirata K; Cicciarelli J; Iwaki Y
Artif Organs; 1996 Aug; 20(8):849-52. PubMed ID: 8853794
[TBL] [Abstract][Full Text] [Related]
8. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro and in vivo activities of two 9-deazaguanine analog inhibitors of purine nucleoside phosphorylase, CI-972 and PD 141955.
Gilbertsen RB; Josyula U; Sircar JC; Dong MK; Wu WS; Wilburn DJ; Conroy MC
Biochem Pharmacol; 1992 Sep; 44(5):996-9. PubMed ID: 1530667
[TBL] [Abstract][Full Text] [Related]
10. Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
Gilbertsen RB; Scott ME; Dong MK; Kossarek LM; Bennett MK; Schrier DJ; Sircar JC
Agents Actions; 1987 Aug; 21(3-4):272-4. PubMed ID: 3120507
[TBL] [Abstract][Full Text] [Related]
11. In vitro study of BCX-34: a new human T-lymphocyte-specific purine phosphorylase inhibitor.
Iwata H; Wada Y; Walsh M; Montgomery JA; Hirose H; Mendez R; Cicciarelli J; Iwaki Y
Transplant Proc; 1998 Jun; 30(4):983-6. PubMed ID: 9636397
[No Abstract] [Full Text] [Related]
12. The biochemistry and pharmacology of PD 116124 (8-amino-2'-nordeoxyguanosine), an inhibitor of purine nucleoside phosphorylase (PNP).
Dong MK; Scott ME; Schrier DJ; Suto MJ; Sircar JC; Black A; Chang T; Gilbertsen RB
J Pharmacol Exp Ther; 1992 Jan; 260(1):319-26. PubMed ID: 1530976
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of deoxyguanosine lymphotoxicity. Human thymocytes, but not peripheral blood lymphocytes accumulate deoxy-GTP in conditions simulating purine nucleoside phosphorylase deficiency.
Fairbanks LD; Taddeo A; Duley JA; Simmonds HA
J Immunol; 1990 Jan; 144(2):485-91. PubMed ID: 2104895
[TBL] [Abstract][Full Text] [Related]
14. Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.
Bennett LL; Allan PW; Noker PE; Rose LM; Niwas S; Montgomery JA; Erion MD
J Pharmacol Exp Ther; 1993 Aug; 266(2):707-14. PubMed ID: 8355201
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological properties of CI-972, a novel 9-deazaguanine analog purine nucleoside phosphorylase (PNP) inhibitor.
Gilbertsen RB; Dong MK; Wilburn DJ; Kossarek LM; Sircar JC; Kostlan CR; Conroy MC
Adv Exp Med Biol; 1991; 309A():41-4. PubMed ID: 1789255
[TBL] [Abstract][Full Text] [Related]
16. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
17. PD 141955 and CI-972: 9-deazaguanine analog purine nucleoside phosphorylase inhibitors. I. Suppression of the human mixed lymphocyte reaction (MLR).
Wilburn DJ; Dong MK; Gilbertsen RB
Agents Actions; 1993; 39 Spec No():C96-8. PubMed ID: 8273599
[TBL] [Abstract][Full Text] [Related]
18. 8-Amino-9-substituted guanines: potent purine nucleoside phosphorylase (PNP) inhibitors.
Sircar JC; Kostlan CR; Pinter GW; Suto MJ; Bobovski TP; Capiris T; Schwender CF; Dong MK; Scott ME; Bennett MK
Agents Actions; 1987 Aug; 21(3-4):253-6. PubMed ID: 3120506
[TBL] [Abstract][Full Text] [Related]
19. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes.
Kicska GA; Long L; Hörig H; Fairchild C; Tyler PC; Furneaux RH; Schramm VL; Kaufman HL
Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4593-8. PubMed ID: 11287638
[TBL] [Abstract][Full Text] [Related]
20. 2'-deoxyguanosine toxicity for B and mature T lymphoid cell lines is mediated by guanine ribonucleotide accumulation.
Sidi Y; Mitchell BS
J Clin Invest; 1984 Nov; 74(5):1640-8. PubMed ID: 6334099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
